Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDCT in symptomatic lumbar intervertebral disc degeneration
NCT03347708Phase 1Completed
- Sponsor
- DiscGenics
- Start
- Feb 2018
- Primary completion
- Feb 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rebonuputemcel in degenerative disc disease (DDD) (4 arms), sponsored by DiscGenics. Primary endpoints: Number of Adverse Events at 2 years and Visual Analog Scale for Pain at 1 year. Started Feb 2018; status: completed.
02
Drugs
rebonuputemcel
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03347708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347708.